AARDEX Group Announced as Founder Member of CancerX Initiative to Drive Innovation in the Fight Against CancerAdherence specialists join multi-stakeholder initiative to improve long-term pathways for cancer patients and meet the challenge of oral treatments18 July 2023 -- Liege, Belgium --
Adherence specialist AARDEX Group is proud to announce it is a founding member of the CancerX initiative, bringing together diverse stakeholders to drive innovation and improve follow up for cancer patients. The public-private partnership announced by The White House is part of the reignited Cancer Moonshot. It is primarily focused on advancing digital innovation to improve equity and reduce financial toxicity in cancer care and research.
For many patients, cancer becomes a chronic condition and improving patient dosing is therefore vital to enhance treatment individualisation and increase medication adherence. Although CancerX is a national US-initiative, EU companies like AARDEX bring a special touch and unique approaches. This includes PRECIDOSE, AARDEX’s AI precision dosing technology, which is revolutionising medication adherence in daily healthcare settings.
Bernard Vrijens, CEO and scientific lead at AARDEX Group, said: “We need to change how we think about the pathway of cancer treatment. Yes, it is initially about killing the cancer cells, but it then becomes a chronic disease for most patients. We need to make sure those patients are receiving appropriate doses and not experiencing too many side effects. Side effects are the number one driver for stopping treatment. Adherence technology can help develop appropriate dosing pathways. It can also help to tackle a growing adherence challenge as more cancer drugs are delivered orally. We are delighted to bring our unique adherence insight and technology to help tackle these challenges head on through the CancerX initiative.”
CancerX is co-hosted by the Moffitt Cancer Center and the Digital Medicine Society (DiMe).
Santosh Mohan, vice president, Digital at Moffitt Cancer Center, commented: “Beating cancer demands bold innovation and deliberate collaboration. CancerX is creating a dynamic ecosystem where ideas can flourish, expertise and resources can be shared, and innovative solutions can be rapidly developed and equitably deployed in the fight against cancer. As a co-host, we take immense pride in the diverse and inclusive community of pioneers coming together as members, all driven by a shared commitment to advancing the goals of the Cancer Moonshot. Together, we will advance the frontiers of cancer research and treatment through digital innovation, while striving to reduce the incidence and burden of cancer for all people.”
“Multi-stakeholder collaboration is critical to harness the potential of digital innovation in the fight against cancer, and we’re honoured to partner with AARDEX Group to achieve the ambitious goals of CancerX,” commented Smit Patel, associate programme director at DiMe: “Through this impressive collaboration, we will establish best practices, build capacity and demonstrate the impact of innovation on the life of every person on a cancer journey.”About AARDEX Group
At AARDEX Group, we believe in the power of digital solutions to revolutionise the way we measure and manage medication adherence. We're not just talking the talk; we're walking the walk as the global leader in this space. Our cutting-edge technology, MEMS Adherence Software (MEMS AS), is the cornerstone of a comprehensive ecosystem designed to deliver accurate, data-driven adherence analytics across all forms of drug administration. But we don't stop there. Our team is dedicated to continuously innovating and pushing the boundaries of what's possible in the world of clinical trials. Our mission is simple yet ambitious: to empower patients and revolutionize the way we approach medication adherence through the use of data and technology. At AARDEX, we're not just making a difference; we're leading the charge. Visit: www.aardexgroup.com